Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

Front Immunol. 2023 Mar 3:14:1107866. doi: 10.3389/fimmu.2023.1107866. eCollection 2023.

Abstract

Introduction: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination.

Methods: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months.

Results: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26-50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60-90 days, decreased, and stabilized at 82.9% at 181-240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported.

Discussion: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations.

Keywords: COVID-19; cellular immune response; inactive vaccine; kinetics; neutralizing antibody.

Publication types

  • Observational Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Neutralizing
  • COVID-19 Vaccines* / immunology
  • COVID-19* / prevention & control
  • China
  • Female
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prospective Studies
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • COVID-19 Vaccines
  • spike protein, SARS-CoV-2

Grants and funding

This work was supported by the Henan Provincial Key Programs in Science and Technology [grant numbers 202102310355 and 182102311241] to YY and WY, and the Joint Program of Medical Science and Technology Research of Henan Province [grant numbers SB 201903018, LHGJ 20190611, and LHGJ 20200016] to YY and BW.